RT Journal Article
SR Electronic
T1 Association of SARS-CoV-2 Genomic Load with COVID-19 Patient Outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.02.20145151
DO 10.1101/2020.07.02.20145151
A1 Zacharioudakis, Ioannis M.
A1 Prasad, Prithiv J.
A1 Zervou, Fainareti N.
A1 Basu, Atreyee
A1 Inglima, Kenneth
A1 Weisenberg, Scott A.
A1 Aguero-Rosenfeld, Maria E.
YR 2020
UL http://medrxiv.org/content/early/2020/07/04/2020.07.02.20145151.abstract
AB Rationale The Infectious Diseases Society of America has identified the use of SARS-CoV-2 genomic load for prognostication purposes as a key research question.Objectives We explored the SARS-CoV-2 genomic load as a risk factor for adverse patient outcomes.Methods A retrospective cohort study among adult patients admitted to the hospital between March 31st to April 10th, 2020 with COVID-19 pneumonia was conducted. We segregated patients into 3 genomic load groups: low (Cycle threshold (Ct) ≥35), intermediate (25<Ct<35), and high (Ct≤ 25) using real-time polymerase chain reaction.Measurements A composite outcome of death, intubation, and/or extracorporeal membrane oxygenation was used. Secondary outcomes included the severity of pneumonia on admission, as measured by the Pneumonia Severity Index (PSI).Main Results Of 457 patients with COVID-19 pneumonia from March 31st to April 10th, 2020, 316 met inclusion criteria. Included patients were followed for a median of 25days (IQR 21-28). High genomic load at presentation was associated with higher Charlson Comorbidity Index (p=0.005), transplant recipient status (p<0.001), and duration of illness less than 7 days (p=0.005). Importantly, patients with high genomic load were more likely to reach the primary endpoint (p=0.001), and had higher PSI scores on admission (p=0.03). In multivariate analysis, a high genomic load remained an independent predictor of the primary outcome. Results remained significant in sensitivity analyses.Conclusions Our findings suggest that a high genomic load of SARS-CoV-2 at the time of admission is an independent predictor of adverse outcomes, that above and beyond age, comorbidity, and severity of illness on presentation, may be used to risk-stratify patients, and call for a quantitative diagnostic assay to become available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved with a waiver of informed consent by the New York University Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data were generated at NYU Langone Health, New York. Derived data supporting the findings of this study are available from the corresponding author on request.